Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. - Wikidata - awgldk - TriplyDB

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

http://www.wikidata.org/entity/Q39476063

about

Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy Membranous nephropathy: not just a disease for adults Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy Genetic and epigenetic factors influencing chronic kidney disease Insights into kidney diseases from genome-wide association studies.Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy Concurrent IgG4-related tubulointerstitial nephritis and IgG4 myeloperoxidase-anti-neutrophil cytoplasmic antibody positive crescentic glomerulonephritis: A case report.Membranous nephropathy: from models to man Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis.Antiphospholipase A₂ receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy.Retrospective Study of Phospholipase A2 Receptor and IgG Subclasses in Glomerular Deposits in Chinese Patients with Membranous Nephropathy Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy.Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy Changing the concepts of immune-mediated glomerular diseases through proteomics.Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy Membranous Nephropathy: A Journey From Bench to Bedside Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases.Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.Biomarkers to detect membranous nephropathy in Chinese patients.The role of complement in membranous nephropathy.Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.Immunopathogenesis of membranous nephropathy: an update.Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications.Immunology of membranous nephropathy: from animal models to humans.Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms.Membranous nephropathy: thinking through the therapeutic options.Primary Membranous Nephropathy.Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy.Membranous nephropathy in the kidney allograft.A Proposal for a Serology-Based Approach to Membranous Nephropathy.

P2860

Q26747416-100E5C3F-C877-4C3B-A631-5FB2310BD4C4 Q26866206-D0E18830-BAB8-49A0-BD90-1DAF29921BBD Q27023372-979B2351-0233-4BED-BDC7-F92915619CEA Q27024548-E78A889D-C604-44B6-804A-2370599606CC Q30248678-0B933DDB-5DDB-4A66-AD32-BF812842853D Q33660542-315D9133-8E34-4C9E-B8A9-4CF9598A9B22 Q33714308-86D0CA93-3C9A-4D92-8873-F221A24845BF Q33872569-81B8A665-07FA-40C7-913F-79CB5DDAD85F Q34008949-1F4BF336-A537-4DF6-A033-F0B9349071F5 Q34455214-4B40A749-0D3F-4FBD-96BF-6068F8C930C5 Q34700533-32B92466-B948-42E1-9E06-0B29EB835B28 Q35027267-6FF21EA5-292D-4CEE-828B-694036D76D77 Q35148727-0AC07598-45B5-4939-B092-FC20D80CCC54 Q35165809-E8BD7D4B-CDBF-46F0-B821-C831C834D0C3 Q35782970-685CB79B-AE84-473D-8AC0-A604FE8B3733 Q36029138-A38DD5E9-A3C0-4B9A-A644-726DC2068F2A Q36063886-40B7568C-60F0-432F-A16A-D3269A95A7AF Q36104805-7DC7591A-3FE3-4C20-9A69-FC71CCC0031A Q36201993-2194C5C8-C764-49C2-B11B-D77A82CE1167 Q36296621-DAEBDC79-F2AA-45A6-958E-EFCB35A8A83B Q36849177-A5FB2DB2-1547-4F18-B51E-89BA9166AA2D Q37020995-C29FD008-563C-43DE-ABA6-75D2DC5E6126 Q37038576-B8C95E13-56DA-48DA-B40C-084A3492A5B4 Q37042246-97418919-8F16-43B9-8AB7-864FBD37CBCC Q37135113-8D8B526F-4EC1-412D-8322-42B609A3D259 Q37254679-7DC2BCFD-F083-4622-98C0-47EA2E31B196 Q37475696-8F297D86-3912-4C5E-B416-B2119F78F0BD Q37553082-DDEDBE21-775B-4ED8-B398-BBD21268FA92 Q37708722-215940EC-7048-41B7-ADB7-5EAD59DADECF Q38155652-5D89CEC0-ECA0-4F7A-A556-B92CE19ED182 Q38185614-1A4C6534-1004-421E-8EB9-F02D230D4C43 Q38203172-E24B12FF-D52E-48DA-BCAD-6EF8A8A55FDD Q38371343-2E05745A-BEA6-42BC-B95B-E9B42FAD60AF Q38605469-11698BDD-8585-4747-9DBF-4113DA495993 Q38711526-34E601B6-F863-4A83-B993-7F2C05F70CBC Q38733002-E5F855BE-2FBF-403D-8950-2881104F95DF Q38760741-F6FDE293-D2A6-4030-85FF-9ED52ED00A79 Q38843422-FB6A8056-71BC-47C6-A3CD-5E9E7CEBE057 Q38959093-497E9169-FE50-4D69-9D44-27F64D4694F3 Q38989854-3BFF46A3-9DF4-4A15-9FBF-3A4C1641602D

P2860

Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

http://www.wikidata.org/entity/Q39476063

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@en

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@nl

type

label

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@en

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@nl

prefLabel

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@en

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@nl

P1433

Q39476063-B64643C3-2FE2-41E8-9143-028B5FDD7BD3

P1476

Q39476063-9D2138B1-9D27-44C0-B830-A73BF4B4EDA7

P2093

Q39476063-170927F4-338E-44F0-8E6A-CA00279DE905

Q39476063-2A98FBEF-3A29-40DA-9765-E48D7D077440

Q39476063-5BB06337-1BBF-4DEE-B054-68950827B93A

Q39476063-612CAFBB-AA43-45DA-9807-956CCB1619FE

Q39476063-8B47603B-D908-41E4-AB0B-7CE3BD562889

Q39476063-C80CC8EE-B092-4553-9C4D-B70E9973D953

Q39476063-D2529859-B9BD-43BF-9AEB-DFDDE56BEEDF

Q39476063-DA3A41D3-5B04-4959-A146-6A481ED63160

P2888

Q39476063-D072C431-731D-4EEA-A0DA-115152287290

P304

Q39476063-5949905B-3E7E-4EBB-B5F3-FA31A1FBB0A5

P31

Q39476063-773D0331-5544-48BD-AD4B-45B3761B9C70

P356

Q39476063-98DC8FE5-6936-45DE-9A8A-3A18315F2C8F

P407

Q39476063-517C5F7E-05F7-4726-91D7-B30B031CEF50

P433

Q39476063-CA9A3BC0-348F-46E8-99D3-4E4C8A7372B1

P478

Q39476063-037BE1D9-06CE-4193-8141-CB48B2E3CBCF

P50

Q39476063-4BAB7F00-CC64-44BE-9ED1-8A18A3B05AB2

Q39476063-8204EB23-D917-4E58-920D-956DF2495D7D

Q39476063-EC8F33E8-1A2C-410D-935D-BB0C3CDEA04A

P577

Q39476063-55782506-2230-4F53-AE63-3EC6DDEC078A

P698

Q39476063-81F215A5-D662-417C-8624-FEB794777710

P921

Q39476063-0DC84711-0A78-4737-92EB-4D73D6BDCE19

P356

P1433

Kidney International

P1476

Anti-PLA2R antibodies measured ...... pathic membranous nephropathy.

@en

P2093

Colin D Short

http://www.w3.org/2001/XMLSchema#string

Durga Kanigicherla

http://www.w3.org/2001/XMLSchema#string

Edward A McKenzie

http://www.w3.org/2001/XMLSchema#string

Jennet Gummadova

http://www.w3.org/2001/XMLSchema#string

Kay Poulton

http://www.w3.org/2001/XMLSchema#string

Lorna McWilliam

http://www.w3.org/2001/XMLSchema#string

Michael Venning

http://www.w3.org/2001/XMLSchema#string

Shelley Harris

http://www.w3.org/2001/XMLSchema#string

P2888

P304

940-948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2012.486

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Stephen A. Roberts

Paul E Brenchley

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23364522

http://www.w3.org/2001/XMLSchema#string

P921